ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Seattle Genetics, a biotech firm known for its antibody-drug conjugate platform, has come up with a new technology that increases the potency of monoclonal antibodies. The company’s sugar-engineered antibody technology prevents fucose from being incorporated into the carbohydrate chains of monoclonal antibodies, making the drugs better at evoking an immune response. Adding these modified sugars to cell-culture media doesn’t change the antibody manufacturing process, yield, or product quality. The new technology will be incorporated into Seattle Genetics’ early-stage pipeline and could be partnered with other companies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter